![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety and Efficacy of TBR-652, a Chemokine Receptor 5 (CCR5) Antagonist, in HIV-1-Infected, Antiretroviral (ARV) Treatment-Experienced, CCR5 Antagonist-Naïve Patients
|
|
|
Reported by Jules Levin
17thCROI, San Francisco, February 16-19, 2010
Calvin Cohen, MD*
Research DirectorCommunity Research Initiative of New EnglandHarvard Medical School
*On behalf of TBR-652-2-201 Study Team
from Jules: this CCR5 drug has a potentially unique characteristic in that it also binds CCR2 which appears to have potentially a clinically anti-inflammatory effect. The company will explore this in future studies. In the last slide you can see the binding inhibition of drug to MCP-1 which is a reflection of its anti-inflammatory affect.
![image002.gif](../images/022210/022210-2/image002.gif)
![image004.gif](../images/022210/022210-2/image004.gif)
![image006.gif](../images/022210/022210-2/image006.gif)
![image008.gif](../images/022210/022210-2/image008.gif)
![image010.gif](../images/022210/022210-2/image010.gif)
![image012.gif](../images/022210/022210-2/image012.gif)
![image014.gif](../images/022210/022210-2/image014.gif)
![image016.gif](../images/022210/022210-2/image016.gif)
![image018.gif](../images/022210/022210-2/image018.gif)
![image020.gif](../images/022210/022210-2/image020.gif)
![image022.gif](../images/022210/022210-2/image022.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|